A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Status:
Withdrawn
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to
assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and
effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are
then followed weekly for 12 weeks and afterwards for up to 1 year.